CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 11 enrolled
Drug / intervention
Parathyroid Hormone (1-34)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00377312
NCT00377312Early Ph 1Completed
CompareCT.gov

Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation

University of Pittsburgh·interventional·Posted Sep 18, 2006·Updated Mar 22, 2016

In Brief

A Early Phase 1 clinical trial evaluating Parathyroid Hormone (1-34) for Osteoporosis and 2 related conditions. Completed, enrolled 11 participants across 1 site.

Detailed Summary

Study consists of an eight day inpatient visit on the General Clinical Research Center. The investigators' specific aims are to: 1. To define the maximum safe dose of a seven day continuous administration of parathyroid hormone \[PTH(1-34)\] in healthy human volunteers. 2. To estimate the effect of a seven day continuous administration of parathyroid Hormone (PTH) in escalating doses on vitamin D metabolism, markers of bone turnover and fractional excretion of urine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Early Ph 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 18, 2006
Enrollment StartSep 1, 2006
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.8 years ago

Interventions

Parathyroid Hormone (1-34)drug

PTH(1-34) IV given over a one week period